Buckle-up Kids.  Our Derms on Drugs are answering some of the hottest questions in dermatology again this week:

• Melanoma's Mental Massacre: Discover which patients are most likely to spiral into anxiety and depression after diagnosis and how we can help save their sanity!
• Biosimilar Backstabbing: Why do patients switched to biosimilars fare worse than newbies to psoriasis? We'll peel back the layers of this pharmaceutical puzzle.
• Eczema Epidemic Exposed: Hold onto your moisturizers, folks! We've cracked the code on why everyone and their itchy grandmother has atopic dermatitis. Spoiler alert: It's not just your genes being jerks!
• Air Pollution: The Silent Skin Assassin: Dr. Ian Myles spills the tea on how he caught air pollution red-handed in the great eczema explosion of the '70s. Urban dwellers, your skin's arch-nemesis has been unmasked!

But wait, there's more! We'll also dive into:

• The return of the zit: Predicting acne's revenge after isotretinoin
• Dupilumab: The accidental cancer crusader?
• Tralokinumab: Savior for dupilumab dropouts or just another letdown?
• Ferulic acid vs. Rosacea: The face-off you never knew you needed
• Cysteamine and hydroquinone duke it out in the melasma arena
• Digital mucous cysts: Because even your fingers deserve some drama

You’ll laugh, you’ll cry, you might even learn something new… Join Drs. Ferris, Zirwas and Patton for a new episode every Friday

Derms on Drugs is produced by ⁠Scholars in Medicine.⁠

Guest: Ian A. Myles, MD, Mph

Guest Bio: Dr. Myles, Principal Investigator, Epithelial Therapeutics Unit, graduated with a B.S. in biology from Colorado State University in 2001 and then obtained an M.D. from the University of Colorado in 2005. He completed an internal medicine residency at The Ohio State University prior to beginning fellowship training in allergy and clinical immunology at NIH. In 2011, Dr. Myles became a commissioned officer in the United States Public Health Service Commissioned Corps. In 2013, he was awarded a position as an assistant clinical investigator in the NIAID Transition Program in Clinical Research. Dr. Myles received his M.P.H. from George Washington University in 2016. In 2018, Dr. Myles became the head of the newly formed Epithelial Therapeutics Unit to evaluate the efficacy and safety of a topical, live bacterial treatment for atopic dermatitis (eczema). He is currently a participant in the Lasker Clinical Research Scholars and Distinguished Scholars programs.

Links to Articles and Websites

1.  Prevalence and odds of anxiety and depression in cutaneous malignant melanoma: a proportional meta-analysis and regression

2.  Drug Survival and Safety of Biosimilars Compared with Originator Adalimumab for Psoriasis: A Multinational Cohort Study

3.  The clinical, mechanistic, and social impacts of air pollution on atopic dermatitis

4.  Exposure to isocyanates predicts atopic dermatitis prevalence and disrupts therapeutic pathways in commensal bacteria

5.  Environmental and behavioral mitigation strategies for patients with atopic dermatitis

6.  Acne Relapse and Isotretinoin Retrial in Patients With Acne

7.  Risk of malignancy associated with use of dupilumab versus other treatments in atopic dermatitis patients: A national database analysis

8.  Tralokinumab Treatment in Adult Atopic Dermatitis Patients: 28-Week Evaluation of Clinical Effectiveness, Safety, Serum Proteins and Total IgE Levels

9.  Ferulic Acid in the Treatment of Papulopustular Rosacea: A Randomized Controlled Study

10.  Efficacy and safety of cysteamine 5% cream for the management of melasma: a systematic review and meta-analysis of randomized controlled trials

11.  Effectiveness of surgical versus non-surgical interventions in treatment of digital mucous cysts

Melanoma Prognosis Calculator

http://www.lifemath.net/cancer/melanoma/outcome/index.php

Skinesa Defensin+ Probiotic Spray

https://www.skinesa.com/products/defensin-probiotic-spray